Wells Fargo raised the firm’s price target on Repligen (RGEN) to $190 from $175 and keeps an Overweight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN: